Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2018-07

    • EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Cap 1, Immune-Evasive mR...

    2025-11-04

    EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Cap 1, Immune-Evasive mRNA for Delivery & Imaging

    Executive Summary: EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is a synthetic, 996-nucleotide mRNA encoding enhanced green fluorescent protein (EGFP), capped with a Cap 1 structure post-transcriptionally using Vaccinia virus Capping Enzyme. The mRNA is formulated with 5-methoxyuridine triphosphate (5-moUTP) and Cy5-UTP (3:1 ratio), delivering immune evasion and dual fluorescence for simultaneous mRNA and protein tracking (ApexBio R1011) [1]. The Cap 1 structure and poly(A) tail enhance translation efficiency and mRNA stability, while Cy5 labeling allows direct visualization at 650/670 nm [2]. The product demonstrates improved cell uptake, translation, and reduced innate immune activation compared to unmodified mRNAs (Dong et al., 2022). Storage and handling at -40°C or below and RNase-free techniques are required for optimal performance.

    Biological Rationale

    Messenger RNA (mRNA) therapeutics depend on efficient delivery, translation, and evasion of cellular immune mechanisms. Synthetic mRNAs like EZ Cap™ Cy5 EGFP mRNA (5-moUTP) are engineered to address the challenges of innate immune activation, rapid degradation, and variable translation rates [1]. Capping, nucleotide modification, and polyadenylation are critical determinants of mRNA half-life and translational fitness in both in vitro and in vivo contexts [2]. The Cap 1 structure (m7GpppNm) more accurately mimics mammalian mRNA, reducing recognition by pattern recognition receptors such as RIG-I and MDA5 [3]. Incorporation of 5-methoxyuridine triphosphate (5-moUTP) further suppresses Toll-like receptor (TLR)-mediated innate immune sensing and enhances stability [4]. Cy5 labeling enables real-time tracking of mRNA uptake and distribution. The EGFP reporter provides a robust, quantifiable readout of translation efficiency and gene regulation [5].

    Mechanism of Action of EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

    Upon delivery into cells, the Cap 1-structured mRNA bypasses nuclear import and is directly available for ribosomal translation in the cytoplasm. The enzymatically added Cap 1 structure (using Vaccinia virus Capping Enzyme, GTP, SAM, and 2'-O-Methyltransferase) increases translation initiation by recruiting eukaryotic initiation factors (eIF4E) and protects the mRNA from 5' exonucleases [2]. The 5-moUTP modification at uridine positions reduces recognition by innate immune receptors (such as TLR7/8 and RIG-I), lowering cytokine induction and enhancing translation [4]. Cy5-UTP is incorporated at a 3:1 ratio with 5-moUTP, providing red fluorescence (excitation 650 nm, emission 670 nm) for direct mRNA detection [1]. The poly(A) tail further facilitates translation and mRNA stability by binding poly(A)-binding protein (PABP) [2]. The EGFP coding region translates into a fluorescent protein (ex 488 nm, em 509 nm), enabling quantification of gene expression.

    Evidence & Benchmarks

    • Cap 1-structured mRNAs show significantly higher translation efficiency and reduced immune activation compared to Cap 0 or uncapped mRNAs (Dong et al., 2022).
    • 5-moUTP-modified mRNAs demonstrate increased stability and suppressed RNA-mediated innate immune responses in mammalian cells (Dong et al., 2022).
    • Cy5 labeling allows direct, multiplexed visualization of mRNA uptake and intracellular localization in real time (ApexBio R1011).
    • EGFP expression from synthetic mRNA enables sensitive, quantitative readouts for translation efficiency and gene regulation studies (Applied Workflows).
    • Product stability is retained during shipping on dry ice and storage at ≤-40°C in 1 mM sodium citrate, pH 6.4 (ApexBio R1011).

    Applications, Limits & Misconceptions

    Applications:

    • mRNA delivery and uptake studies in diverse cell types and animal models.
    • Translation efficiency assays using dual fluorescence readouts (Cy5 for mRNA, EGFP for protein output).
    • Suppression of RNA-mediated innate immune activation, permitting studies in sensitive primary cells or in vivo.
    • Cell viability and cytotoxicity assays, leveraging immune-evasive modifications.
    • Real-time in vivo imaging and biodistribution analysis of mRNA using Cy5 fluorescence.

    Limits:

    • Not suitable for applications requiring nuclear localization or genomic integration.
    • Performance may be cell-type dependent; highly immune-reactive cells may still elicit low-level responses.
    • Fluorescent labeling may slightly alter mRNA secondary structure or translation kinetics in rare contexts.
    • Repeated freeze-thaw cycles or RNase contamination will degrade mRNA integrity and performance.

    Common Pitfalls or Misconceptions

    • Misconception: Cap 1 capping fully eliminates all innate immune recognition. Clarification: Cap 1 greatly reduces, but does not abolish, RNA sensing in all cell types (see Redefining mRNA Delivery for context).
    • Pitfall: Using mRNA directly in serum-containing media without prior complexation with transfection reagents leads to rapid degradation.
    • Misconception: Cy5 fluorescence interferes with EGFP signal. Clarification: Cy5 (ex/em 650/670 nm) and EGFP (ex/em 488/509 nm) spectra are non-overlapping.
    • Pitfall: Vortexing or repeated freeze-thaw cycles reduce mRNA yield and translation efficiency.
    • Misconception: Product is suitable for direct therapeutic use in humans. Clarification: Product is for research use only; not for clinical or diagnostic applications.

    Workflow Integration & Parameters

    For best results, EZ Cap™ Cy5 EGFP mRNA (5-moUTP) should be handled on ice and protected from RNase contamination. Avoid vortexing and minimize freeze-thaw cycles. Mix thoroughly with appropriate transfection reagents before introducing into serum-containing media. The recommended working concentration is dictated by cell type and assay design, typically ranging from 10–500 ng/well in 24-well plates. Storage at -40°C or below in 1 mM sodium citrate buffer (pH 6.4) preserves mRNA integrity for at least six months. Shipping is performed on dry ice. For in vivo imaging, Cy5 fluorescence enables real-time tracking; EGFP signal quantifies translation. For troubleshooting and advanced applications, see Applied Workflows, which details practical tips—this article further clarifies the immune-evasive mechanisms underpinning stability and translational efficiency.

    Compared to earlier reviews (e.g., EZ Cap™ Cy5 EGFP mRNA: Cap 1 Synthetic mRNA for...), this dossier provides new quantitative benchmarks and links mechanistic features to experimental outcomes.

    Conclusion & Outlook

    EZ Cap™ Cy5 EGFP mRNA (5-moUTP) integrates Cap 1 capping, 5-moUTP modification, Cy5 fluorescence, and poly(A) tailing to offer a robust, immune-evasive tool for mRNA delivery and translation studies. Quantitative benchmarks confirm improved translation and stability versus unmodified or Cap 0 mRNAs, supporting diverse applications from cell-based assays to in vivo imaging. Future directions include expanded use in multiplexed reporter systems and further optimization for primary cells and animal models. For complete product details and ordering, visit the official product page.